{{Rsnum
|rsid=17270561
|Gene=SLC17A1
|Chromosome=6
|position=25820211
|Orientation=plus
|GMAF=0.1552
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SLC17A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 3.5 | 33.6 | 62.8
| HCB | 7.3 | 27.0 | 65.7
| JPT | 0.0 | 14.2 | 85.8
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 10.5 | 89.5
| CHB | 7.3 | 27.0 | 65.7
| CHD | 3.7 | 29.4 | 67.0
| GIH | 2.0 | 24.8 | 73.3
| LWK | 0.0 | 0.9 | 99.1
| MEX | 3.4 | 37.9 | 58.6
| MKK | 0.0 | 0.0 | 0.0
| TSI | 3.9 | 26.5 | 69.6
| HapMapRevision=28
}}
{{PMID Auto GWAS
|PMID=19084217
|Trait=Serum markers of iron status
|Title=Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels
|RiskAllele=
|Pval=5E-7
|OR=NR
|ORtxt=NR
|OA=1
}}

{{PharmGKB
|RSID=rs17270561
|Name_s=
|Gene_s=SLC17A1
|Feature=
|Evidence=PubMed ID:19084217; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. (Initial Sample Size: 459 twin pairs; Replication Sample Size: NR); (Region: 6p22.2; Reported Gene(s): SLC17A1; Risk Allele: rs17270561-?); (p-value= 0.0000005).This variant is associated with Serum markers of iron status.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740127
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17270561
|overall_frequency_n=14
|overall_frequency_d=128
|overall_frequency=0.109375
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}